FHTX earnings date and last-quarter result: last quarter miss, P/E -4.45. Updated 2026-07-23.
Foghorn Therapeutics (FHTX) Research Hub
Foghorn Therapeutics (FHTX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 2.05 USD (+2.50%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -4.45, market cap 0.30B. This hub links to the full technical, earnings and options research available for FHTX.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.05 USD (+2.50%) |
| 52-week range | 1.79 USD – 7.35 USD |
| Trend regime | Range |
| 14-day RSI | 55.4 (Bullish) |
| Trailing P/E | -4.45 |
| Market cap | 0.30B |
| Dividend yield | 0.00% |
Available research for FHTX
Covered Call on FHTX: how it works, illustrative setup around the real 2.05 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on FHTX: how it works, illustrative setup around the real 2.05 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on FHTX: how it works, illustrative setup around the real 2.05 USD price, max profit/loss, breakeven and when to use it. Educational.
FHTX technical analysis: range, last 2.05 USD, RSI 55.4, 52w range 1.79 USD–7.35 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is FHTX in?
Foghorn Therapeutics (FHTX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is FHTX in an uptrend or downtrend?
As of 2026-10-26, FHTX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is FHTX's trailing P/E ratio?
FHTX's trailing P/E is -4.45, with a market cap of 0.30B. See the earnings research page for full valuation detail.